Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer.
作者信息
Ehmsen Sidse, Asmussen Anders, Jeppesen Stefan S, Nilsson Anna Christine, Kragh Amalie, Frederiksen Henrik, Ditzel Henrik J
机构信息
Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Oncology, Odense University Hospital, Odense, Denmark.
Department of Hematology, Odense University Hospital, Odense, Denmark.
出版信息
Cancer Cell. 2022 Aug 8;40(8):800-801. doi: 10.1016/j.ccell.2022.06.012. Epub 2022 Jul 1.
Abstract
摘要
相似文献
1
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer.癌症患者在第四次接种新冠病毒mRNA疫苗后抗体滴度升高且血清阴性率降低。
Cancer Cell. 2022 Aug 8;40(8):800-801. doi: 10.1016/j.ccell.2022.06.012. Epub 2022 Jul 1.
2
Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination.癌症患者第三次新冠mRNA疫苗接种后的抗体反应及第四次接种的潜在时机
Cancer Cell. 2022 Apr 11;40(4):338-339. doi: 10.1016/j.ccell.2022.02.011. Epub 2022 Feb 24.
3
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.利妥昔单抗治疗患者中第四剂 COVID-19 疫苗的免疫原性和安全性：一项开放性扩展研究。
Ann Rheum Dis. 2022 Dec;81(12):1750-1756. doi: 10.1136/ard-2022-222579. Epub 2022 Aug 17.
4
[SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].血液系统疾病患者接种 COVID-19 mRNA 疫苗（BNT162b2）后针对 SARS-CoV-2 刺突蛋白的 IgG 反应
Rinsho Ketsueki. 2022;63(4):247-253. doi: 10.11406/rinketsu.63.247.
5
Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.简要研究报告：通过基于 mRNA 的 COVID-19 疫苗接种，癌症免疫疗法的长期应答者对 SARS-CoV-2 免疫。
Front Immunol. 2022 Jul 5;13:908108. doi: 10.3389/fimmu.2022.908108. eCollection 2022.
6
'Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 vaccine.接种 BNT162b2 mRNA COVID-19 疫苗后出现“蓝色脚趾”。
J Travel Med. 2021 Jun 1;28(4). doi: 10.1093/jtm/taab024.
7
Humoral response after a fourth "booster" dose of a Coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients.在透析患者中，基于mRNA的疫苗接种3剂方案后，接种第4剂2019冠状病毒病疫苗“加强针”后的体液免疫反应。
Kidney Int. 2022 Jun;101(6):1289-1290. doi: 10.1016/j.kint.2022.04.006. Epub 2022 Apr 12.
8
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.抗肿瘤治疗的癌症患者接种 BNT162b2 冠状病毒病 2019 信使 RNA 疫苗后体液免疫应答降低。
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.
9
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.比较 BNT162b2 mRNA 疫苗接种者的恢复期和未接种者的 SARS-CoV-2 抗刺突蛋白 RBD IgG 和中和抗体与 COVID-19 患者的动力学。
BMC Med. 2021 Aug 23;19(1):208. doi: 10.1186/s12916-021-02090-6.
10
Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients.癌症患者中BNT162b2和ChAdOx1新冠疫苗接种后S1抗体滴度的比较。
ESMO Open. 2022 Apr;7(2):100414. doi: 10.1016/j.esmoop.2022.100414. Epub 2022 Feb 7.
引用本文的文献
1
Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.2019冠状病毒病疫苗接种对癌症患者的影响：安全性、有效性及长期影响
Support Care Cancer. 2025 Aug 4;33(8):753. doi: 10.1007/s00520-025-09783-1.
2
Effects of antineoplastic and immunomodulating agents on postvaccination SARS-CoV-2 breakthrough infections, antibody response, and serological cytokine profile.抗肿瘤和免疫调节剂对疫苗突破性 SARS-CoV-2 感染、抗体反应和血清细胞因子谱的影响。
J Immunother Cancer. 2024 Jan 31;12(1):e008233. doi: 10.1136/jitc-2023-008233.
3
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.癌症患者和接受 HSCT 或 CAR-T 治疗患者的 COVID-19 疫苗接种：免疫反应、真实世界疗效以及对未来的影响。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S55-S69. doi: 10.1093/infdis/jiad174.
4
Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9).来自2022年欧洲白血病感染会议（ECIL 9）的血液系统恶性肿瘤、造血干细胞移植和CAR-T治疗患者COVID-19管理建议更新
Leukemia. 2023 Sep;37(9):1933-1938. doi: 10.1038/s41375-023-01938-5. Epub 2023 Jul 17.
5
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.SARS-CoV-2 疫苗在血液系统恶性肿瘤患者中诱导的体液和细胞免疫。
Semin Hematol. 2022 Oct;59(4):192-197. doi: 10.1053/j.seminhematol.2022.11.001. Epub 2022 Nov 19.
6
Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy.免疫治疗癌症患者的 SARS-CoV-2 疫苗接种的纵向疗效和毒性。
Cell Death Dis. 2023 Jan 20;14(1):49. doi: 10.1038/s41419-022-05548-4.
7
COVID-19 Vaccines, Effectiveness, and Immune Responses.新型冠状病毒肺炎（COVID-19）疫苗、有效性和免疫应答。
Int J Mol Sci. 2022 Dec 6;23(23):15415. doi: 10.3390/ijms232315415.
本文引用的文献
1
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.BNT162b2 和 mRNA-1273 新冠疫苗作为两剂 ChAdOx1 nCoV-19 或 BNT162b2 疫苗后的第四剂加强针，以及一剂 BNT162b2 疫苗后的第三剂加强针的安全性、免疫原性和反应原性：一项多中心、盲法、2 期、随机试验。
Lancet Infect Dis. 2022 Aug;22(8):1131-1141. doi: 10.1016/S1473-3099(22)00271-7. Epub 2022 May 9.
2
Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination.癌症患者第三次新冠mRNA疫苗接种后的抗体反应及第四次接种的潜在时机
Cancer Cell. 2022 Apr 11;40(4):338-339. doi: 10.1016/j.ccell.2022.02.011. Epub 2022 Feb 24.
3
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.三剂 BNT162b2 mRNA COVID-19 疫苗在标准两剂接种失败的 CLL 患者中的疗效。
Blood. 2022 Feb 3;139(5):678-685. doi: 10.1182/blood.2021014085.
4
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.严重急性呼吸综合征冠状病毒 2 疫苗在胸部癌症患者中的疗效：一项支持在两剂疫苗接种后血清学应答轻微的患者中接种第三剂疫苗的前瞻性研究。
J Thorac Oncol. 2022 Feb;17(2):239-251. doi: 10.1016/j.jtho.2021.10.015. Epub 2021 Nov 16.
5
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
6
Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study.实体瘤癌症患者感染 SARS-CoV-2 的严重程度和 1 个月预后：一项丹麦全国队列研究。
Acta Oncol. 2021 Jul;60(7):859-865. doi: 10.1080/0284186X.2021.1889659. Epub 2021 Mar 1.
7
Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.中国武汉癌症患者 COVID-19 疾病严重程度相关的临床特征和危险因素：一项多中心、回顾性、队列研究。
Lancet Oncol. 2020 Jul;21(7):893-903. doi: 10.1016/S1470-2045(20)30309-0. Epub 2020 May 29.
Zotero 插件